
We see precision medicine as the future of cancer care.
Let’s make it happen, together. Our cutting-edge genomic profiling technology covers all cancer and sample types to accelerate precision cancer care. We work closely with you to solve your specific needs, with a relentless focus on quality and efficiency.
EXPERIENCE MATTERS.WE HAVE IT.
Services for Oncology Clinical Trials
-
- NGS services
- CDx + LDT strategy
- Project management
- Sample logistics and storage
- Data analysis and storage
- Customized QC/QA solutions
NGS Services for Precision Oncology
-
- Pan-cancer genetic test for solid tumors
- ctDNA liquid biopsy
- Over 30 clinical NGS testing products for different cancers
- Over 10 products under development
NGS-based CDx Kit for Diagnosis
-
- Essencare ™ EGFR/ALK/ROS1/BRAF/KRAS/HER2 mutant testing kit (reversible terminator technology)
NGS Services for Research
-
- DNA sequencing
- WGS, WES
- Targeted panel sequencing
- DNA methylation sequencing
- Customer-made library sequencing
- RNA sequencing
- Whole transcriptome sequencing
- Small RNA sequencing, including miRNA, siRNA and piRNA
- Circular RNA sequencing
- DNA sequencing

900,000+
SAMPLES
sequenced for cancer patients

800+
HOSPITALS
in which our products are used

50+
PRODUCTS
for solid tumors & blood cancers

2000+
CLINICAL PROJECTS
in translational research

550+
PUBLICATIONS
in the past 5 years
Certified to the highest international clinical lab standards




Genomic Testing
The most diverse range of cancer genomic testing available
Using comprehensive genomic insights, we help match cancer patients to optimal treatments, including targeted therapy and immunotherapy. Our pan-cancer panel analyzes 400+ genes, while specific panels target individual cancer types. We partner with you to give you the insights you need to take action – from treatment decisions to new therapy development.
Research Services
A strong partner to drive research forward
Our company is built on a strong foundation of research, with deep scientific expertise and active R&D. We have 2000+ research projects with biopharma and research partners, providing high-quality genomic data to accelerate translational research. We offer full research services, including project design & management, next-generation sequencing, QC/QA and data analysis, tailored to your needs.


OUR TECHNOLOGY
Reliable and fast is possible
We are continuously evolving our sequencing technology as we gain new knowledge. This ensures an optimized workflow – from sample preparation, mutation calling and data mining to machine-learning and exclusive genomic databases – and a very high sequencing capacity. To date, we have sequenced 900,000+ samples (360,000+ liquid biopsy samples), with high sensitivity and specificity and a turnaround time of just five business days.
LET’S ACCELERATE PRECISION CANCER CARE, TOGETHER.
Learn more about our products and services or contact us today to discuss how we can partner together.
Our News
October 17, 2023
Geneseeq to present four studies at ESMO 2023
Toronto, Oct.17th 2023-Geneseeq Technology Inc. is excited to share…
October 13, 2023
GENESEEQ RECEIVES CHINESE NMPA APPROVAL FOR LUNG CANCER TUMOR MUTATIONAL BURDEN NGS TEST KIT
Toronto Oct.13th –Geneseeq Technology Inc. announced on Thursday that…
August 22, 2023
Geneseeq Gains CE Marks for NGS-based Test Kits for Solid Tumors and Hematological Cancer
Toronto- Aug. 22nd- Geneseeq Technology Inc. has announced that three…
May 25, 2023
GENESEEQ TO SHOWCASE NEW FINDINGS AT ASCO 2023
Toronto, May 25- Geneseeq Technology Inc. is set to present four…
May 16, 2023
Geneseeq published new research on the clinical use of circulating-free DNA fragmentomic in monitoring minimal residual disease for patients with non-small-cell lung cancer
TORONTO, May 16, 2023 – The majority of cancer-related deaths…
April 13, 2023
Geneseeq co-publish with UHN on using ctDNA as a prognostic biomarker for immunotherapy
TORONTO, April 13, 2023 – Geneseeq co-published a study with Princess…
March 9, 2023
Geneseeq and Collaborators Initiate MOTION Study to Evaluate the Performance of Minimal Residual Disease Test SHIELDING™ in Early-stage Lung Cancer
March 09, 2023, Toronto - This week, Geneseeq Technology Inc. has…
January 24, 2023
Geneseeq receives CE Marks for MRD and MCED tests.
TORONTO - Jan 24, 2023 - Geneseeq Technology Inc. announced that…
November 3, 2022
Geneseeq study evaluates the clinical value of cell-free DNA 5’-end motif profile in the prediction of pathological complete response for LARC patients after neoadjuvant chemoradiotherapy
TORONTO, November 3, 2022 – In recent years, the 'Wait and Watch'…
October 18, 2022
Geneseeq study highlights ctDNA monitoring clinical value in colorectal cancer patients resistant to BRAF/EGFR-targeted therapy
TORONTO, 18 Oct, 2022 – Colorectal cancer (CRC) is the second leading…
Stay in the loop! Subscribe our newsletter
Error: Contact form not found.